Cloonan Michael's Form 4 filing
Sionna Therapeutics, Inc. (SION) · filed Sep 18, 2026
- Accession no.
- 0001704336-26-000005
- Filed
- Sep 18, 2026, 4:52 PM ET
- Trade date
- Sep 17, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cloonan MichaelCIK 0001704336 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Common Stock | AGrant or awardAcquired | +109,025 | $0.00 | $0 | 656,368 | Direct | |
| Sep 17, 2026 | Common Stock | AGrant or awardAcquired | +109,025 | $0.00 | $0 | 765,393 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
Referenced by the price of 2 transactions in Table II.